Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06949410 · ClinicalTrials.gov registry record · Phase 1
HER2 Vaccine for Locally Advanced Breast Cancer
A Phase 1 study of Breast Cancer and HER2-positive Breast Cancer, sponsored by Pravin T.P Kaumaya.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06949410 is a Phase 1 study of Breast Cancer and HER2-positive Breast Cancer that is actively recruiting participants, run by Pravin T.P Kaumaya. The registered enrollment target is 36 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06949410, a Phase 1 study of Breast Cancer and HER2-positive Breast Cancer, is actively recruiting participants, sponsored by Pravin T.P Kaumaya.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.
Conditions Studied
Interventions
- DRUG HER2 Vaccine
Study Locations (1)
Indiana
- Indiana University Melvin & Bren Simon Comprehensive Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-03 |
| Est. Completion | 2030-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06949410
The ClinicalTrials.gov registry entry for NCT06949410 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Pravin T.P Kaumaya, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which HER2 Vaccine is the first listed.
NCT06949410 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT06949410 about?
NCT06949410 is a clinical study titled "HER2 Vaccine for Locally Advanced Breast Cancer". The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.
What is the current status of trial NCT06949410?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2026-03. Estimated completion is 2030-03.
What conditions does trial NCT06949410 study?
This clinical trial studies the following conditions: Breast Cancer, HER2-positive Breast Cancer.
What interventions are being tested in trial NCT06949410?
The interventions under investigation include: HER2 Vaccine (DRUG).
Who is sponsoring clinical trial NCT06949410?
This trial is sponsored by Pravin T.P Kaumaya, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06949410 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.